The secondary objectives include the comparison of alternative-mechanism-TNFi and abatacept to rituximab in terms of disease response , quality of life , toxicity , safety and structural and bone density outcomes over a @-month period ( @weeks ) and to evaluate the cost-effectiveness of switching patients to alternative active therapies compared to current practice .